Subhasis Banerjee

The evolution of therapeutic modalities drives the adoption of single-use technologies.

This study on a recombinant human follicle stimulating hormone demonstrates the use of virus filters to reduce the risk of contamination.

Membrane-based TFF technology can ease scale-up and provide a higher recovery percentage compared to conventional purification methods.